KDR and hepatocellular carcinoma: Lenvatinib mainly inhibits various receptors and pathways within cells, such as VEGFR, platelet-derived growth factor receptors (PDGF), fibroblast growth factor receptors (FGFR) and hepatocyte factor receptor (c-KIT), to inhibit cell proliferation, promote cell apoptosis, and block angiogenesis, thereby achieving the effect of treating HCC (Laface et al., 2022).